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Abstract. Antimicrobial prophylaxis in neutropenic
patients has been practised in one form or another for
t
several decades but the goal is no longer clear. From 
being initially solely an attempt at decontamination, 
drugs such as co-trimoxazole and later the fluoro­
quinolones were preferred to non-absorbable regi­
m ens because they achieve reliable protection against 
bacteraemia due to Gram-negative bacilli. Neverthe­
less, fever still invariably occurs during neutropenia 
leading to the initiation of traditional empirical 
therapy. Not only is this approach illogical but it also 
ignores the flexibility afforded the oral and parenteral 
formulations of the fluoroquinolones, Instead, it 
m ight be as effective and less costly if these agents 
were given orally until the end of neutropenia unless 
there was evidence of malabsorption or poor oral 
intake, in which case treatment would be continued 
parenterally. Should patients develop fever, an
attempt would be made to complement treatment 
with another anti-microbial agent for microbiologi- 
cally or clinically defined infection. This would be car­
ried out at diagnosis, before any changes in the 
prophylactic regimen could be made. Otherwise, 
treatment with the prophylactic regimen would con­
tinue without modification. There is a less compelling 
need for prophylaxis against candidosis, herpes sim­
plex and cytomegalovirus disease as these would be 
better managed pre-emptively when there is evidence 
of yeast carriage or re-activation of viral infection. 
Similarly, prophylaxis of aspergillosis is a forlorn hope 
and again a pre-emptive approach might serve us 
better once there is a screening test available and a 
safe and effective drug.
Keywords: prophylaxis, neutropenia, quinolone, drug 
availability, alternative approach.
Introduction
Since the mid-1970s, antimicrobial agents have been 
given to patients undergoing treatment for haemato- 
logical malignancy to reduce infectious complications 
arising during neutropenia [1]. The rationale under­
pinning the approach was primarily to suppress the 
resident Gram-negative bacilli such as Escherichia coli 
and to prevent the acquisition of others such as 
Klebsiella pneumoniae and Pseucfomo/ias aeruginosa in 
order to reduce the risk of infection and fulminant 
sepsis which was a major cause of death. At the time, 
fungi were not perceived as great a threat as now and 
viral infections were largely untreatable as there were 
no antiviral agents available. In the intervening 
period, the opportunity for considering prophylaxis 
against mycosis and viral infection presented itself as 
new  agents became available for treating herpes sim­
plex virus (HSV) and cytomegalovirus (CMV) infec­
tion candidosis and also aspergillosis. However, the
question of how best to employ these agents remains 
a thorny issue as the answer depends very largely 
upon whether a given infection is perceived or known 
to lead to unacceptably high morbidity or mortality 
which is considered avoidable.
Neutropenic patients do not form a homogenous 
group of patients and so are not at equal risk of infec­
tion nor is the infection-related morbidity and mor­
tality always the same. A broad consensus has been 
reached in terms of prophylactic practices for bone- 
marrow transplant recipients because the principal 
infection risks are fairly predictable and mostly pre­
ventable. By contrast, there is no uniform approach
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to either the use or the nature of prophylaxis in 
patients who become neutropenic following remis­
sion induction and consolidation courses of chemo­
therapy. Therefore, an  appraisal of the rationale for 
antimicrobial prophylaxis can only be pursued by 
considering the prevention of bacterial, viral and 
fungal infections separately.
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Antibacterial prophylaxis
The aim of prophylaxis of bacterial infections was ini­
tially simply to suppress the Gram-negative bacilli 
such as Escherichia coll Klebsiella pneumoniae (for­
merly Klebsiella aerogenes) and Pseudomonas aerogenes 
(also known as Pseudomonas pyocyanea) at source, 
namely, the gastrointestinal tract as it had been 
observed that colonization invariably preceded infec­
tion. At first, non-absorbable regimens such as gen- 
tamicin plus vancomycin plus nystatin were given in a 
futile attempt to sterilize the gut. Interest soon shifted 
to partial or selective decontamination (SDD) with 
framycetin (or neomycin) plus colistin (or polymyxin 
B) plus a polyene antifungal agent, as it had been 
shown in mice that preservation of the anaerobic 
flora was necessary to sustain colonization resistance 
[2]. Antifungal agents were included to prevent over­
growth of yeasts rather than candidosis. The gradua­
tion to co-trimoxazole occurred soon afterwards 
when it was also shown to lower the incidence of 
infections caused by Gram-negative bacilli while at 
the same time affording protection against infection 
from Pneumocystis carinii. As co-trimoxazole was 
given at therapeutic doses leading to both systemic 
and gut decontamination its use was a significant 
departure from the original concept that motivated 
prophylaxis. Meanwhile, partial antibiotic decontam­
ination continued to have its advocates who used a 
regimen of nalidixic acid in addition to the non­
absorbable polymyxins, aminoglycosides and a 
polyene or miconazole [3],
Although no single placebo-controlled trial of any 
regimen, whether absorbable or not, was sufficiently 
large to provide a conclusive answer, almost every 
such study showed a clear trend towards reducing 
infection caused by Gram-negative bacilli [4]. Several 
studies then followed which helped co-trimoxazole 
become the standard agent for many centres particu­
larly when its lack of activity against Pseudomonas 
aeruginosa could be largely compensated for by using 
colistin [5].
Co-trimoxazole or a fluoroquinolone?
The introduction of the fluoroquinolones in the early 
1980s further expanded the range of agents with nor­
floxacin, ciprofloxacin, ofloxacin and pefloxacin all 
shown to be effective in reducing bacteraemia due to 
Gram-negative rods [6 ]. However, in common with all
their predecessors, their use has little influence on 
fever-related and infection-related mortality. Nor do 
these agents possess any useful activity in vitro against 
Gram-positive cocci particularly the coagulase-nega- 
tive staphylococci [7-9] and the viridans streptococci 
[1 0 ] which have become the two most common causes 
of bacteraemia in neutropenic patients [11], The fluo­
roquinolones appear better tolerated, are much less 
likely to induce skin rash than co-trimoxazole and are 
preferred for patients receiving cytarabine which can 
itself cause a cutaneous drug reaction.
Problems with antibacterial prophylaxis
Despite the variety of studies undertaken, antibac­
terial prophylaxis has had no measurable impact on 
overall survival, mortality attributable to infections 
caused by Gram-negative bacilli, or on remission rates 
[1,12], Moreover, the fall in mortality due to Gram- 
negative sepsis probably owes more to the prompt 
institution of empirical broad spectrum therapy as 
soon as neutropenic patients become febrile and more 
effective treatment of the underlying disease. Indeed, 
the mortality attributed to Gram-negative sepsis 
remains around 10-15% whether or not prophylaxis 
has been employed. However, only approximately 
1 0 % of patients develop this type of infection making 
the global mortality approximately 1-2% [13,14]. 
Finally, prophylaxis can actually diminish the quality 
of life because of side-effects and the effort often 
needed to comply.
Coagulase-negative staphylococci
Bacteraemia due to these bacteria is clearly related to 
the widespread use of intravascular catheters which 
become colonized, although the oral cavity and gas­
trointestinal tract might also be reservoirs [15]. 
Typically, these staphylococci are multiply resistant to 
sulphonamide, trimethoprim, methicillin, gentamicin 
and erythromycin as well as to the fluoroquinolones if 
one has been used for prophylaxis. A potential expla­
nation for this has been recently suggested by the 
demonstration that ciprofloxacin is excreted in sweat 
at concentrations that correspond with those found in 
plasma and that Staphylococcus epidermidis, with the 
typical pattern of multiple resistance, can be detected 
in the axillary flora within 2  days of starting 
750mgbd. Similar strains were also found at a later 
stage in the nose and both these and their axillary
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counterparts persisted for 3-4 weeks after stopping 
th e  drug, A similar mechanism may well apply to co- 
trimoxazole so it must be concluded that selection of 
these resistant staphylococci is an immediate and 
inevitable consequence of using these drugs for pro­
phylaxis. Moreover, their evolution will increase the 
likelihood of their appearing sooner or later in the 
blood stream via either an intravascular catheter or 
through the oral and nasal and possibly gut lesions 
th a t result from severe mucositis.
*
Oral viridans streptococci
Bacteraemia caused by the oral viridans streptococci 
has also increased in frequency and was first noted 
after prophylaxis co-trimoxazole [16-19]. The fluoro­
quinolones also appear to predispose certain patients 
to  streptococcal bacteraemia by giving the bacteria a 
selective advantage [20]. Exposure to ciprofloxacin is 
more likely to predispose to bacteraemia caused by 
these streptococci than is found for co-trimoxazole 
when low doses of cytarabine are used [21], By con­
trast, the nature of cytostatic chemotherapy appears 
a  more important risk factor than does antimicrobial 
prophylaxis when high doses of cytarabine are used 
for chemotherapy. This is almost certainly due to the 
degree and severity of mucositis induced by chemo­
therapy as Streptococcus oralis and Streptococcus mitis 
are the two most common isolates from blood cultures 
and both are normal microbial residents of the oral 
cavity They also exhibit median MICs of 2 -4  mg/L 
ciprofloxacin [2 2 ] which straddles the peak serum 
levels of the drug following a 500 mg oral dose in 
neutropenic patients [23].
Selection of other natively resistant bacteria
The application of selective pressure on natively resis­
tant bacteria is one of the inevitable consequences of 
employing any antimicrobial agent for prophylaxis for 
decontaminating body sites and providing adequate 
systemic concentrations. Thus, apart from oral ‘viri- 
dans' streptococci and coagulase-negative staphylo­
cocci, 5iom£i£ococcus mucilaginosus, Bacillus spp, 
lactobacilli, and enterococci are easily selected by 
exposure to fluoroquinolones because of their 
marginal susceptibility. The same is true for Gram- 
negative bacteria such as Stenotrophomonas 
(Xanthomonas) maltophilia, Prophylaxis therefore 
alters the epidemiology of infection, sometimes in an
unpredictable way but more often in directions that 
can be anticipated by knowledge of the dominant 
flora of the neutropenic population. It is therefore 
unwise for any particular centre to adopt anti­
bacterial prophylaxis without first understanding its 
own infectious epidemiology and attempting to fore­
cast the likely benefits and disadvantages of employ­
ing any particular regimen.
Selection of resistant Gram-negative bacilli
Almost as soon as co-trimoxazole was adopted for pro­
phylaxis, there were reports of emergent resistance 
[24]. Bacteraemia due to fluoroquinolone resistant 
Escherichia coli has also occurred in neutropenic 
patients following treatment with ofloxacin [25], 
pefloxacin [26], and norfloxacin [27] and it is prob­
ably only a matter of time before similar cases are 
reported following ciprofloxacin. This is a matter of 
concern and should encourage regular surveillance of 
the oral cavity and bowel as the resistant bacteria can 
be detected in the faeces before the onset of fever [28].
Impact of cytoreductive chemotherapy on 
drug availability
The protection afforded by fluoroquinolones and, to a 
lesser extent, co-trimoxazole is not confined to decon­
tamination but is also provided systemically as these 
drugs are given at therapeutic doses most of which is 
absorbed and therefore available to the tissues. 
However, the pharmacokinetics of ciprofloxacin have 
been shown to alter following treatment with chemo­
therapy with peak concentrations being about half 
those expected 13-15 days after starting treatment 
[23]. This has been attributed to reduced absorption 
owing to the toxicity induced by chemotherapy 
[23,29]. This has also been confirmed for ofloxacin. 
The International Antimicrobial Therapy Cooperative 
Group of the European Organisation for Research and 
Treatment of Cancer has also noted that serum levels 
of pefloxacin were lower in patients who became 
febrile than  in patients who did not [30] as were those 
of trimethoprim [31]. Drug levels are therefore at 
their lowest at the onset of profound neutropenia 
and fever and infection. Mucositis also occurs around 
this time suggesting that drug levels drop as the 
chemotherapy begins to exert its toxic effects on the 
mucosa and bone marrow namely, mucositis and 
neutropenia. The absorption of xylose is also reduced
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1following treatment with cytarabine [32 J and gut per­
meability markedly increases following conditioning 
therapy for bone-marrow transplant [33]. Moreover, 
this is also about the same time that patients suffer 
most from nausea and vomiting so even if absorption 
is not impaired, compliance is likely to be poor. Lower 
drug levels may well allow less susceptible bacteria, 
such as the viridans streptococci, to survive in the 
bloodstream after invasion from damaged oral 
mucosa. Invasion may also emanate from the bowel if 
it becomes colonized as a result of reduced gastric 
acidity induced by H2 antagonists which may present 
a risk factor for the sepsis syndromes such as adult 
respiratory distress syndrome (ARDS) are associated 
with bacteraemia caused by Streptococcus mitis [18].
Why does antibacterial prophylaxis fail?
These observations beg the question of whether pro­
phylaxis fails because of intrinsic inactivity of the 
drug or because less of the drug is available? This is 
important because prophylaxis is considered to have 
failed and is invariably stopped as soon as fever devel­
ops and is replaced by an empirical regimen of a P-lac- 
tam with or without an aminoglycoside which affords 
essentially the same spectrum of activity against 
Gram-negative bacilli. This is because it is assumed 
that any pathogen involved in the putative infectious 
process must be resistant to prophylaxis. However, 
such pathogens are usually coagulase-negative 
staphylococci and viridans streptococci rather than 
Gram-negative bacilli, and typical empirical regimens 
are not considered optimal without the early addition 
of a glycopeptide [9,34-36]. The switch from oral 
prophylaxis to broad-spectrum parenteral therapy 
maintains the protection against Gram-negative 
bacillary infection albeit with different compounds 
but the automatic progression from prophylaxis to 
empirical therapy when fever occurs is not entirely 
logical.
Prophylaxis against candidosis
Candida spp. particularly Candida albicans are common 
residents of the oral cavity and alimentary tract and, 
occasionally; the skin and are classical opportunists 
causing diseases that range from superficial mucosal 
infections to deep-seated candidosis. However, apart 
from Candida tropicalis which has a relatively high 
likelihood of proceeding from colonization to infec­
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tion [37,38], there are no features that mark out the 
potential pathogens from harmless commensal 
species.
The polyenes, amphotericin B and nystatin are 
highly active in vitro against Candida spp. and have 
been employed to suppress the overgrowth of C an ­
dida that tends to accompany treatment with 
antibacterial agents [39,40] and hence lessen the 
risk of infection which is invariably preceded by colo­
nization and mostly occurs in carriers [37,38]. 
However, at least 4.5 MU of nystatin must be given 
every day before there is any significant impact on 
C a n d id a  colonization in either the oral cavity or gut. 
This is difficult to achieve as the drug is unpalatable 
and infections can still occur despite as much as 
30MU/day [39,41,42]. Amphotericin B is more 
effective in suppressing colonization provided at least 
1.5-2 g/day is given [43] and the patient is willing to 
tolerate another unpleasant drug suspension. Also, 
amphotericin B was never licensed in the USA for 
oral administration which may partly explain the 
complete lack of placebo-controlled trials of suffi­
cient numbers of patients to show a significant differ­
ence with a power of at least 80%.
The early azoles clotrimazole and miconazole have 
not fared much better even though both appear to 
prevent oral candidosis without having any marked 
effect on colonization [44]. Once again there have 
been no adequate controlled trials of either of these 
agents. Moreover, neither these agents nor the 
polyenes, provide systemic levels when given orally.
When first introduced, ketoconazole seemed to 
offer the ideal characteristics for an antifungal agent 
against candidosis, being active in vitro and able to 
deliver effective concentrations both systemically and 
locally. After many prophylactic studies of this drug 
[45] it was only found to be effective against muco­
cutaneous candidosis of the oral cavity oesophagus 
at doses of 400-600 mg/day which were higher 
than anticipated or considered desirable. Moreover, 
absorption is variable and is impaired by H2 receptor 
antagonists and, while treatment with ketoconazole 
reduces colonization with Candida albicans there is an 
increase in faecal overgrowth with Candida glabrata 
[45,46]. The drug also interacts with P4 5 0  cyto­
chrome oxidase enzymes causing cyclosporin to be 
released with the consequent risk of nephrotoxicity to 
transplant recipients. Compliance is better than that 
obtained with polyenes but the drug failed to find a 
place in the prevention of candidosis. It was only
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when the triazole fluconazole was introduced that the 
issue of prophylaxis against candidosis could be prop­
erly assessed. Fluconazole offers flexible dosing with 
bioequivalence of oral and parenteral administration 
and  is effective at 50 mg/day in both treating and pre­
venting oral candidosis [47]. A placebo-controlled 
study in adult bone-marrow transplant recipients and 
another in patients undergoing chemotherapy for 
acute leukaemia showed the benefit of 400 mg/day 
fluconazole in reducing both superficial and systemic 
candidosis. A rapid reduction in colonization of the 
alimentary tract with Candida albicans but not Candida 
krusei was also achieved [48,49]. Other investigators 
achieved similar results with 150 mg/day calling into 
question the need for 400 mg/day fluconazole [50]. 
In  any case, since candidosis is almost always pre­
ceded by mucosal colonization, it is surprising that 
there has been no attempt to look at the potential 
benefit of antifungal prophylaxis only in patients who 
actually carry Candida spp. on their mucosal surfaces.
Apart from selecting natively resistant non­
albicans Candida, including Candida glabrata and 
Candida krusei, prophylaxis with fluconazole might 
also lead to the development of superinfection by 
Aspergillus fumigatus [51]. There is also anxiety that 
resistance might emerge among Ca?idida albicans as 
has been observed in patients with AIDS as a result of 
long-term treatment for oral candidosis [52]. 
However, neutropenic patients are very unlikely to 
require prolonged treatment and do not generally 
have persistent or recurring oral candidosis.
Prophylaxis against aspergillosis
Aspergillus spp. are opportunistic pathogens of the air­
ways and only disseminate at a terminal stage. The 
spores are airborne and ubiquitous and colonize the 
nasal cavity, sinuses or bronchi before invading the 
tissues and causing disease. Not surprisingly there 
have been several attempts at interrupting spore 
transmission by using aerosols of 1 0 - 2 0  mg ampho­
tericin B daily with variable success. Many of these 
trials were initiated in response to a sudden sharp rise 
in the incidence of invasive aspergillosis and none 
were randomized. Therefore, any reduction in infec­
tion rates might have been due simply to the seasonal 
variation in airborne spore burden or a cessation of 
building activities which are associated with high 
spore counts. Indeed, an interim analysis of random­
ized trials is still ongoing, but has failed thus far to
show a significant reduction in the incidence of inva­
sive pulmonary aspergillosis [53].
Giving amphotericin B prophylactically has also 
been tried in bone-marrow transplant recipients but 
in a placebo-controlled trial of 0 .1 mg/kg/day 
amphotericin B (known affectionately as Ampho- 
Lite) failed to offer any benefit to those who received 
the drug [54]. The costs and infusion-related compli­
cations were not favourable and the nephrotoxic 
potential of amphotericin B also precludes its use 
when cyclosporin is being given to prevent graft- 
versus-host disease in allogeneic bone-marrow trans­
plantation. Amphotericin B given intravenously at
0.5 mg/kg three times a week did not offer any advan­
tage over 400 mg/day fluconazole to neutropenic 
patients [5 5].
Unlike fluconazole, itraconazole, another triazole, 
is active against aspergillus and is therefore a poten­
tial candidate for prophylaxis against both candidosis 
amd aspergillosis. Unfortunately, only oral prepara­
tions of the drug have been available for study and 
absorption appears to be erratic, especially during 
neutropenia [56]. Indeed, a recent double-blind trial 
of 400 mg/day together with oral amphotericin B 
failed to show any benefit against candidosis or 
aspergillosis [57]. Itraconazole might offer some pro­
tection to bone-marrow transplant recipients [44] 
although interactions with cyclosporin have occurred 
with 200 mg/day [58].
Interactions of azoies and other drugs
Co-administered antacids lower the plasma concen­
trations of ketoconazole and itraconazole by decreas­
ing absorption and both H2-receptor antagonists and 
sucralfate impair the uptake of ketoconazole. Drugs 
such as rifampicin and phenytoin increase the 
metabolism of ketoconazole, itraconazole and flu­
conazole whereas the ketoconazole and itraconazole 
both increase the plasma concentrations of 
cyclosporin, phenytoin, tolbutamide, midazolam, 
triazolam, astemizole as well as the vinca alkaloids 
vincristine and vinblastine by inhibiting their 
metabolism [59].
Is there actually a need for prophylaxis 
against candidosis and aspergillosis?
Although there is considerable concern that systemic 
mycosis is increasing, there are few reliable data on
© 199 7 Blackwell Science Ltd Journal of Internal Medicine 242 (Supplement 740): 79-88
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the actual prevalence, partly because diagnosis is usu­
ally made post-mortem [60] and autopsy rates are 
low, particularly in Europe [44]. The incidence of dis­
seminated candidosis have to be gleaned from prophy­
lactic studies mentioned earlier and suggest a 
prevalence of < 1 0 % despite prophylaxis and approxi­
mately twice this figure when none is used. Therefore, 
the case for giving fluconazole prophylactically is not 
very compelling and it may be better to restrict pro­
phylaxis to those most at risk of candidosis, namely 
carriers of Candida albicans who are colonized at one 
or more sites [38,61] or who have in excess of
400 cfu/mL saliva [62].
The prevalence of invasive pulmonary aspergillosis 
is even more difficult to ascertain as it depends upon 
local factors including seasonal variation and hospi­
tal building activity [63]. Furthermore, removing 
spores physically from the air using HEPA filters is 
much more likely to reduce exposure and hence the 
risk of infection. Therefore, there is no convincing 
case for prophylaxis against aspergillosis although 
itraconazole does confer benefit for maintaining pro­
tection against relapse or reinfection once the disease 
has essentially been cured [44].
Antiviral prophylaxis
In the early 1980s it was established that acyclovir 
could protect neutropenic patients from mucocuta­
neous HSV infection [64-66] its use as prophylaxis 
quickly became standard practice for bone-marrow 
transplant recipients but not for those undergoing 
chemotherapy for acute leukaemia. Acyclovir can 
also afford protection against infectious diseases 
caused by varicella-zoster virus following bone-mar­
row transplantation but it is not considered cost-effec­
tive to maintain prophylaxis for more than 3 months 
post-transplant [67]. Acyclovir has no reliable influ­
ence on infections caused by CMV. The morbidity and 
mortality attributed to HSV infection is considered by 
some to be insufficient to warrant routine prophylaxis 
[6 8 ]. Moreover, there is usually a period after trans­
plant when swallowing becomes difficult and many 
patients then receive the drug parenterally causing a 
considerable increase in costs. Unfortunately there 
has been no pharmaco-economic assessment of pro­
phylaxis but given the ability to detect HSV rapidly it 
might be more cost-effective to treat pre-emptively 
when there is evidence of reactivation rather than 
continue universal prophylaxis. By contrast, a pre­
emptive approach to managing CMV infective disease 
has more or less become established practice and 
involves treatment with ganciclovir only when there 
is evidence of active CMV infection before disease 
becomes manifest [69].
An alternative approach to prophylaxis
For antimicrobial prophylaxis to continue to form 
part of the routine supportive care of neutropenic 
patients, its nature and goals must be radically re­
appraised. The primary goal of prophylaxis in 
neutropenic patients remains the prevention of 
Gram-negative infection which can be achieved by 
using the fluoroquinolones [70-72]. However, we 
have not made the best use of these drugs which are 
available in both an oral and parenteral formulation 
and therefore afford flexibility which has been fore­
gone unwittingly because of the essentially artificial 
distinction between prophylaxis and therapy. As 
mentioned earlier, it would actually be much more 
rational to switch from oral to intravenous adminis­
tration when a patient becomes febrile to maintain 
suppression of Gram-negative bacilli rather than 
changing to the more traditional empirical regimens 
which essentially provide the same spectrum of 
activity.
The use of oral ciprofloxacin for prophylaxis has 
been recently shown to reduce the need for parenteral 
therapy [73]. The drug was given to 53 adults under­
going cytotoxic treatment of haematological malig­
nancy for 60 episodes of neutropenia and was 
complemented with ceftazidime and vancomycin in 
5 5 episodes because of fever. Ceftazidime was discon­
tinued after 24-48 h in 40 (91%) of 44 episodes 
because there was no evidence of Gram-negative 
bacillary infection and both vancomycin and oral 
prophylaxis were continued. Treatment was further 
complemented with metronidazole, rifampin or flu­
conazole in 18 of these episodes. The approach only 
failed in four episodes, one of which involved bacter- 
aemia caused by Pseudomonas aeruginosa, Thus, con­
tinuing prophylaxis with a fluoroquinolone to 
maintain protection against Gram-negative bacillary 
infection until bone-marrow recovery and comple­
menting the regimen with specific agents only when 
the need arises seems a viable alternative to conven­
tional practice (Fig. 1). Better results might also be 
obtained if the drug was administered parenterally 
when malabsorption is likely to occur, or the patient is
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Fig. 1 A typical neutropenic episode is depicted in the figure. Prophylaxis with a fluoroquinolone is started orally before chemotherapy is 
begun and continued until bone-marrow recovery. The drug is administered intravenously when malabsorption is likely to occur, or the 
patient is unable to tolerate oral medication, or drug levels are low. Should fever develop, every attempt would be made to identify the cause 
before altering treatment as prophylaxis should protect against rapid deterioration owing to Gram-negative baciliary infection. The 
prophylactic regimen would then only need to be complemented with a specific agent when a microbioiogically defined infection is identified 
or with another agent determined by the nature of a clinically defined infection, e.g. amphotericin B for a pulmonary infiltrate or sinusitis. 
Fluconazole would be started pre-emptively if carriage of CimcMi spp. is identified or for oral candidosis and acyclovir would be given when 
herpes simplex virus is reactivated. Prophylaxis would be stopped prematurely if there was a Gram-negative baciliary infection, deterioration 
of vital signs associated with organ failure or shock or because of intolerance or a potentially harmful drug interaction. A wait-and-see 
approach would be adopted for persistent unexplained fever.
unable to tolerate oral medication. This manoeuvre 
alone might prevent bacteraemia caused by viridans 
streptococci and other Gram-positive cocci while 
maintaining cover against Gram-negative baciliary 
infection.
If patients do develop fever, rather than automati­
cally switching to empirical therapy, every attempt 
would be made to identify the cause before altering 
treatment. Prophylaxis would thus protect against 
rapid deterioration owing to Gram-negative baciliary 
infection thereby allowing time to attempt to diagnose 
the cause of fever. The prophylactic regimen would 
then only need to be complemented with a specific
agent when a microbioiogically defined infection is 
identified or with another agent determined by the 
nature of a clinically defined infection, e.g. ampho­
tericin B for a pulmonary infiltrate or sinusitis, metron­
idazole for a potentially anaerobic infection of the oral 
cavity of gut, fluconazole for oral candidosis or acy­
clovir for HSV infection. In the unlikely event of a 
Gram-negative bacilliary infection, treatment would 
have to be changed altogether to a more appropriate 
regimen. A wait-and-see approach could be adopted for 
fever that persists but remains unexplained.
Clearly, the details and nature of complementary 
therapy would have to be tailored to the needs of the
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individual patients in any particular institution. 
Nevertheless, the experience of two large studies of 
empirical therapy for fever in neutropenic patients 
show that the reasons for complementing initial treat­
ment are limited and that glycopeptides and ampho­
tericin B are the most common drugs given [13,14], 
The optimum dose of drug for prophylaxis would have 
to be determined for maintaining serum levels 
throughout neutropenia using an oral dose that 
achieves 70-80% of the bioavailability provided by 
the parenteral route. For ciprofloxacin this would be 
an oral dose of 750mgb.d. and a parental dose of 
400mgt.d.s. [74], There would also have to be ade­
quate safeguards such as regular surveillance for 
resistant Gram-negative bacilli in oral and faecal sam­
ples as well as in blood cultures and a readiness to 
obtain appropriate specimens for establishing a diag­
nosis of oral, cutaneous and lung infections.
As for candidosis, HSV and CMV infection, a pre­
emptive approach appears more logical and may 
prove more cost-effective as treatment would only be 
initiated with fluconazole for carriers of Candida spp. 
and with acyclovir and ganciclovir, respectively when 
HSV and CMV re-activate.
Conclusion
Such a strategy would have to be formerly tested 
against the more conventional approach to prophy­
laxis leading to empirical therapy and should be sub­
jected to a thorough pharmaco-economic analysis 
with all that that entails. At the moment there is 
probably insufficient interest in re-evaluating the 
role of fluoroquinolones in managing infectious 
complications during neutropenia even though 
there is a scientific need to do so and financial con­
straints demand better husbanding of scarce health­
care resources. Clearly, there would need to be a 
commitment to continuous microbiological surveil­
lance of important body sites as well as the patient’s 
environment in order to recognize colonization with 
potential pathogens, detect disease activity and 
maintain detailed monitoring of resistance. But if 
this approach to prophylaxis were to prove cost- 
effective, the savings could be diverted to improving 
diagnosis while giving the clinician enough confi­
dence to stay his hand and wait rather than treat 
empirically and the microbiologist the opportunity 
of having a more direct and immediate input in 
patient care.
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